Tango Therapeutics(TNGX) - 2024 Q1 - Quarterly Results

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights – Dose expansion initiated in TNG908 phase 1/2 clinical trial – TNG908, a blood-brain barrier penetrant, MTA-cooperative PRMT5 inhibitor TNG462, a potentially best-in-class MTA-cooperative PRMT5 inhibitor – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation ongoing in TNG260 and TNG348 clinical-stage preci ...